SEC Comment Letter for Merck & Co., Inc. (MRK) (CIK 0000310158) (MRK) — Apr 28, 2025

Merck & Co., Inc. (MRK) (CIK 0000310158)
Date: April 28, 2025 · CIK: 0000310158 · Accession: 0000000000-25-004462

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

Date

April 28, 2025

Author

Finance

Form

UPLOAD

Company

Merck & Co., Inc. (MRK) (CIK 0000310158)

Letter

Re: Merck & Co., Inc. Form 10-K for Fiscal Year Ended December 31, 2024 File No. 1-06571 Dear Caroline Litchfield:

April 28, 2025

Caroline Litchfield Executive Vice President and Chief Financial Officer Merck & Co., Inc. 134 East Lincoln Ave. Rahway, NJ 07065

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,
Division of Corporation
Finance
Office of Life Sciences

Show Raw Text

<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 April 28, 2025

Caroline Litchfield
Executive Vice President and Chief Financial Officer
Merck & Co., Inc.
134 East Lincoln Ave.
Rahway, NJ 07065

 Re: Merck & Co., Inc.
 Form 10-K for Fiscal Year Ended December 31, 2024
 File No. 1-06571
Dear Caroline Litchfield:

 We have completed our review of your filing. We remind you that the
company and
its management are responsible for the accuracy and adequacy of their
disclosures,
notwithstanding any review, comments, action or absence of action by the staff.

 Sincerely,

 Division of Corporation
Finance
 Office of Life Sciences
</TEXT>
</DOCUMENT>

SecProbe.io